You are here

Rheumatoid Arthritis and Psoriasis Trials for Vitaxin Halted

GAITHERSBURG, Md., Aug. 30 /PRNewswire-FirstCall/ -- MedImmune, Inc. (Nasdaq: MEDI) announced today that it has decided to terminate Phase 2 testing of Vitaxin(R) in patients with rheumatoid arthritis (RA) and psoriasis based on preliminary data suggesting lack of clinical benefit in these inflammatory diseases. There were no safety concerns identified in the preliminary analyses. MedImmune's oncology program for Vitaxin continues to advance with studies in melanoma and prostate cancer.

About Vitaxin
Vitaxin targets the alpha-v beta-3 integrin, which is a protein expressed on the surface of newly forming blood vessels, certain tumor types and on a number of other cell types, including macrophages and osteoclasts. Based on preclinical models, the alpha-v beta-3 integrin has been implicated in a number of disease processes, including the growth and metastasis of tumors, the bone destruction in RA and the inflammatory process in psoriasis.

Source: MedImmune, Inc.

Recent Headlines

Drug resistance in HIV patients has nearly tripled since 2001
New drug addresses bacterial resistance to standard therapy
Hovering flights lower packages by cable and winch
Ziextenzo helps lower the incidence of febrile neutropenia
The answer may offer a potential treatment for the disease
Drug resistance in HIV patients has nearly tripled since 2001
The number of those with an annual drug spend of $250K or more has increased by 60%
Grading manufacturers would give high-quality, reliable makers a boost, says federal panel
Sharpless is heading back to NCI